A5036187133- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Endometrial and Cervical Cancer Treatments
- Protein Tyrosine Phosphatases
- Chromatography in Natural Products
- Cancer, Lipids, and Metabolism
- Axon Guidance and Neuronal Signaling
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Uterine Myomas and Treatments
- HER2/EGFR in Cancer Research
- Immune Response and Inflammation
- Ovarian cancer diagnosis and treatment
- Gastric Cancer Management and Outcomes
- Angiogenesis and VEGF in Cancer
- Sarcoma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Reproductive System and Pregnancy
- Cervical Cancer and HPV Research
University of Cincinnati Medical Center
2014-2016
University of Cincinnati
2015
Memorial Sloan Kettering Cancer Center
2015
Sabin Vaccine Institute
2014
AstraZeneca (United Kingdom)
2008-2012
The Netherlands Cancer Institute
2012
AstraZeneca (Netherlands)
2012
Cancer Research UK Manchester Institute
2010
University of Manchester
2010
Abstract Background Colorectal cancer (CRC) is a heterogeneous and biologically poorly understood disease. To tailor CRC treatment, it essential to first model this heterogeneity by defining subtypes of patients with homogeneous biological clinical characteristics second match these cell lines for which extensive pharmacological data available, thus linking targeted therapies most likely respond treatment. Methods We applied new unsupervised, iterative approach stratify tumor samples into...
To test the hypothesis that simultaneous, equipotent inhibition of epidermal growth factor receptor (EGFR; erbB1), erbB2 (human 2), and erbB3 signaling, using novel small-molecule inhibitor AZD8931, will deliver broad antitumor activity in vitro vivo.A range assays was used to model erbB family signaling homodimers heterodimers, including evaluation kinase activity, phosphorylation, proliferation cells, vivo testing a human tumor xenograft panel, with ex phosphorylation downstream...
Angiogenesis is necessary for the development of epithelial ovarian cancer (EOC) by prompting tumor growth and supporting metastatic spread. Anti-angiogenesis agents have been studied extensively as frontline, maintenance recurrent treatment in EOC. Bevacizumab, a monoclonal antibody targeting vascular endothelial factor (VEGF), most widely these first to be approved United States Food Drug Administration platinumresistant Recent clinical trials also investigated VEGF independent pathways...
Abstract A broad range of targeted agents are in early development for treatment solid tumours. It is important that patients receive treatments which tailored to work optimally based on their individual tumour biology. Retrospective analysis clinical data the EGFR tyrosine kinase inhibitor, Iressa, lung cancer demonstrated cell line panels can provide a platform direct therapies towards specific patient subpopulations. In order evaluate colorectal we have characterized panel 49 lines...
•The case presented is that of a primary debulking surgery for presumed ovarian cancer.•Final pathology revealed diffusely metastatic endocervical adenocarcinoma.•After chemotherapy, the patient has remained disease-free 30 months after surgery.
Abstract Genetic and epigenetic features such as KRAS mutation status have been used to define colorectal cancer (CRC) subtypes take treatment decisions. In order develop new targeted drugs, however, it is necessary gain a better understanding of the molecular differences CRC subtypes. We developed unsupervised approach for stratifying tumor samples using genome-wide mRNA expression data. Our method based on iterative application non-negative matrix factorization (iNMF) randomly selected...
482 Background: Colorectal cancer (CRC) is generally stratified based on genetic and epigenetic features, such as KRAS mutation microsatellite instability status. In order to facilitate the development of new targeted drugs treatment regimens, it important redefine CRC at molecular level by identifying subtypes that are relevant for response therapy. Methods: We applied a unsupervised approach iteratively stratifying tumor samples using genome-wide mRNA expression data. The resulting gene...